Kura Oncology Inc (KUR.SG)
| Previous close | 11.20 |
| Open | 10.90 |
| Bid | 11.00 x 0 |
| Ask | 11.20 x 0 |
| Day's range | 10.90 - 10.90 |
| 52-week range | 10.00 - 18.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
– Presentations to highlight preclinical data supporting combination of FTIs with KRASG12C inhibitors and tyrosine kinase inhibitors – SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to
- GlobeNewswire
Kura Oncology to Participate in Upcoming Investor Conferences
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences: A “Leukemia Corporate Panel” discussion at the Cowen Health Care Conference in Boston at 12:50 p.m. ET / 9:50 a.m. P
- GlobeNewswire
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of ziftomenib in NPM1-mutant AML – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML on track to initiate in first half of 2023 – – IND for KO-2806, a next-generation farnesyl transferase inhibitor, cleared by FDA – – $25 million strategic equity investment from Bristol Myers Sq
